Table 1.

Patient characteristics of the review.

First author, year	Participants		Duration	Liver biopsies	Noninvasive fibrosis markers	The effects of Angiotensin blockade on fibrosis
Terui Y, 200230	30 patients with early stages of chronic hepatitis C	RCT	Not mentioned	Yes	Yes	Promising beneficial effects
Rimola A, 200427	128 recurrent hepatitis C after LT	Retrospective cohort study	41 months (median)	Yes	No	Beneficial effects
Rincon D, 200537	123 HCV-patients who received LT	Retrospective cohort study	> 6 months	Yes	No	No beneficial effects
Sookoian S, 200529	23 patients with chronic hepatitis C non-responders	Prospective cohort study	14 months	Yes	No	Beneficial effects
Yoshiji H, 200538	20 patients with chronic hepatitis C	RCT	12 months	No	Yes	Promising beneficial effects
Yoshiji H, 200639	40 patients with chronic hepatitis C	RCT	12 months	No	Yes	Beneficial effects
Debernardi-Venon W, 200740	47 selected cirrhotic patients	RCT	12 months	No	Yes	Promising beneficial effects
Corey KE, 200928	234 patients with hepatitis C	Retrospective cohort study	5.08 years	Yes	No	Beneficial effects
Colmenero J, 200941	14 patients with CHC with liver fibrosis	Uncontrolled open-label study	18 months	Yes	No	Promising beneficial effects
Cholongitas E, 201042	102 recurrent hepatitis C after LT	Retrospective cohort study	13 months (median)	Yes	No	No beneficial effects
Abu Dayyeh BK, 201132	192 patients with hepatitis C	RCT	42 months	Yes	No	No beneficial effects
Hidaka H, 201143	48 selected cirrhotic patients	RCT	12 months	No	Yes	Promising beneficial effects
Kim MY, 201244	85 patients with compensated alcoholic liver fibrosis	RCT	6 months	Yes	No	Promising beneficial effects
Yoshiji H, 201231	110 patients with cirrhosis associated with hepatocellular carcinoma	RCT	48 months	No	Yes	Beneficial effects
Guillaud O, 201345	109 recurrent hepatitis C after LT	Retrospective cohort study	23 months (median)	Yes	No	No beneficial effects

RCT, randomized controlled trial; LT, liver transplantation.